| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal id6133: Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy |
|
Medicine details |
|
| Medicine name | fordadistrogene movaparvovec |
| Formulation | intravenous infusion |
| Reference number | 5217 |
| Indication | Treatment of ambulatory boys aged ≥4 years with a confirmed genetic diagnosis of Duchenne muscular dystrophy (DMD) |
| Company | Pfizer Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 22/03/2023 |
| NICE guidance | id6133: Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy |